Growth-factor signalling
CJC-1295 no DAC
What is it?
The term “CJC-1295 no DAC” is used in supplier catalogues for a GHRH-related peptide without the albumin-binding drug affinity complex. It is often used alongside the name modified GRF(1–29), but those labels are not sufficient to verify the molecular sequence in this attachment.
How it is studied
GHRH-related peptides target a different receptor pathway from ghrelin-receptor secretagogues such as ipamorelin. Removing a long-acting modification can materially change exposure and duration. The actual pharmacology depends on the precise sequence and terminal modifications.
What the evidence shows
The frequently cited 2006 CJC-1295 human trial studied the long-acting form. It should be read as background on that formulation, not as direct evidence for the supplier’s CND5 or CND10 entries. A verified identity is required before selecting a matching evidence base.
Limitations & safety context
The attachment does not give a sequence, analytical identity or pharmacokinetic study for this material. Do not equate “no DAC” with a known duration, guaranteed pulsatility or proven safety. The listed strengths describe contents rather than biological potency or clinical suitability.
Listed specifications
| Reference | Listed contents |
|---|---|
| CND5 | 5 mg |
| CND10 | 10 mg |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.